2050 ABR - how did it start? 1944: - Penicillin G on the market - - - PowerPoint PPT Presentation

Antibacterial resistance (ABR) - how serious can it become?

O’Neill, May 2016: deaths attributable to antimicrobial resistance every year by 2050:

2050

Europe today: 25,000 are dying/year from infections

1944:

• Penicillin G on the market
• Time Magazine, May 15,

1944:

ABR - how did it start?

ABR – the historical picture

Last 30 years:

• nly three

new drug classes ABOVE the line: time when new antibiotics were launched: UNDER the line: when resistant bacteria to that drug was found (color coded)

MRSA

marketed resistance found “INDUSTRIAL SILENCE” Minimal Drug discovery and development

ABR – what caused it?

Regulatory Lack of control/ barriers

Antibiotic Overuse Inapropriate prescribing Extensive agricultural use: profit!

Few new antibiotics/ reluctant industry

ABR

We did!

Regulatory regional lack of control!

The ZinChel project: results

Testing Clinical Isolates of Resistant Bacteria (Ø. Samuelsen, UNN)

Meropenem: last resort antibiotic Zinchel compound ZN148 Meropenem + ZinChel ZN148 Still happy and resistant! Not resistant and dead! Still happy and resistant!

+

What about toxicity in eucaryotic cells (e.g. human cells) and live animals?

• After very large and repeated doses

to healthy mice:

• No animals died, no clinical signs.

I still feel fine!

Studies in live animals: necessary for development of new medicines

Tromsø, February 2016: No destruction of red blood cells!

• ZinChel are zinc-binders
• Red blood cells (RBC)

contain iron

• ZinChel could destroy RBC

ABR - the only way forward – to join forces!!

Global Health Authorities

• Restricting AB misuse
• Funding research
• Funding innovation

National and international political actions!

• Restricting AB misuse
• Funding research
• Funding innovation

Pharmaceutical Industry

Development competence!

ABR

Apocalypse now!

Summary

• 3 new classes of antibiotics in 30 years!
• Not working against the worst bacteria.
• People are dying right now witout cure.
• ZinChel: new discovery - dramatically reduces resistance.
• Making old antibiotics great again?
• Key study finished: in vivo tox: compounds practically

nontoxic!

• Key studies under planning:
• Can Zinchel develop resistance over time?
• Can infected animals be cured?
• If positive after this, development towards clinic will start!

Funding:

Center for Integrative Microbial Evolution, UiO

People:

MSc student Espen Frøvold Msc Ørjan Apeland Msc student Roya Popal Associate Professor Ørjan Samuelsen Dr Silje Lauksund Christopher Frölich Associate Professor Lars Petter Jordheim Associate Professor Annette Bayer Dr Hanna-Kirsti Leiros Professor Pål Rongved Professor Tor Gjøen Dr O. Alexander H. Åstrand Dr Geir Kildahl-Andersen Dr Christian Schnaars Dr Peter Molesworth Dr Bora Sieng PhD student Elvar Örn Viktorsson PhD student Anthony Prandina PhD student Adriana M. S. Andresen

Places:

Thank you for your attention…